A retrospective study of efficacy and safety of itraconazole for treatment of invasive fungal infection in hematologic diseases
- VernacularTitle:伊曲康唑治疗血液病患者侵袭性真菌感染的多中心回顾性分析
- Author:
Yu JI
;
Xiaojun HUANG
- Publication Type:Journal Article
- Keywords:
Hematologic diseases;
Itraconazole;
Hematopoietic stem cell transplantation;
Mycoses
- From:
Chinese Journal of Internal Medicine
2008;47(12):1022-1025
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effieacy and safety of intravenous itraconazole for the treatment of invasive fungal infection(IFI)in patients with hematological disease or undergoing allogeneic hematopoietic stem cell transplantation(HSCT).MethodsSix hundred and sixty-six patients with above mentioned conditions and diagnosed as IFI from January.2007 to July,2007 were enrolled.Intravenous itraconazole was administered at a dose of200 nag every 12 hours for 2 days and followed by 200 mg every 24 hours.Patients were then switched to oral itraconazole according to the clinical situation Responses were determined on the basis of clinical and microbiological criteria.Results The probability of defervescence Was 69.8%and the total response rates among related to itraconazole were the proven.probable and possible IFI patients were 73.7%.68.1%and 68.2%(P=0.380).Adverse effects were found in 58 patients (8.7%).which were mainly mild to medium reversible dysfunction of liver and gastrointestinal tract, Conclusion Itraconazole is an effective and safe antifungal agent for patients with hematological disease or undergoing HSCT and is suitable for empirical antifungal therapy.
